{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-23-000065","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.906699+00:00","generated_at":"2026-06-16T00:51:37.313165+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Castle Biosciences Q1 revenue up 57% to $42M; reaffirms FY 2023 guidance $170-180M","bullets":["Delivered 14,916 total test reports (+73% YoY); DecisionDx-Melanoma 7,583 (+26%), DecisionDx-SCC 2,411 (+111%).","Revenue $42.0M (+57% YoY); adjusted revenue $43.4M (+65%); net loss ($29.2M) vs ($24.6M) prior year.","Gross margin 70.5% (adjusted 76.5%); cash & marketable securities $232.1M as of March 31, 2023.","Reaffirms full-year 2023 revenue guidance of $170-180M; Q1 cash use includes $17.7M non-recurring bonus/benefit payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-23-000065","json":"https://secwatch.observer/filing/0001447362-23-000065.json","markdown":"https://secwatch.observer/filing/0001447362-23-000065.md","text":"https://secwatch.observer/filing/0001447362-23-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000065/0001447362-23-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000065/cstl-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:51:37.313165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98d4878f20bc9c2d16f08ce7a3b49b1f110bb1e3","claim":"CASTLE BIOSCIENCES INC reported the first quarter ended March 31, 2023 results: revenue $42.0 million, net income $(29.2) million. Guidance reaffirmed.","evidence_excerpt":"Castle Biosciences Reports First Quarter 2023 Results Q1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023 revenue is expected to be between $170-180 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000065/0001447362-23-000065-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$42.0 million"},{"label":"Net income","value":"$(29.2) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}